Mayne Pharma : Change of Director's Interest Notice

Appendix 3Y

Change of Director's Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Mayne Pharma Group Limited
ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Scott Anthony Richards
Date of last notice	4 December 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

	Direct or indirect interest	Direct and indirect
	Nature of indirect interest	Solium Nominees (Australia) Pty Ltd as nominee for
	(including registered	Scott Richards (1)
	holder)	HSBC Nominees (Australia) Limited as nominee for Scott Anthony
	Note: Provide details of the	Richards (2)
	circumstances giving rise to the	HSBC Nominees (Australia) Limited as nominee for Scott Anthony
	relevant interest.	Richards & Susan Marie Richards (3)
	Date of change	31 July 2021
	No. of securities held prior	28,869,697 Ordinary Shares pursuant to Executive Share Loan Scheme (1)
	to change	3,862,906 Ordinary Shares (2)
		1,722,463 Ordinary Shares (3)
		3,681,297 Performance Rights pursuant to Performance Right and Option
		Plan
	Class	Ordinary Shares
	Number acquired	Nil
	Number disposed	2,242,005
	Value/Consideration	Not Applicable. Forfeit of employee loan shares pursuant to the
	Note: If consideration is non-cash,	Executive Share Loan Scheme
	provide details and estimated
	valuation

+ See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change

Nature of change

Example: on-market trade, off- market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

26,627,692 Ordinary Shares pursuant to Executive Share Loan Scheme (1) 3,862,906 Ordinary Shares (2)

1,722,463 Ordinary Shares (3)

3,681,297 Performance Rights pursuant to Performance Right and Option Plan

Forfeit of employee loan shares pursuant to the Executive Share Loan Scheme

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

	Detail of contract
	Nature of interest
	Name of registered holder
	(if issued securities)
	Date of change
	No. and class of securities to
	which interest related prior to
	change
	Note: Details are only required for a contract in
	relation to which the interest has changed
	Interest acquired
	Interest disposed
	Value/Consideration
	Note: If consideration is non-cash, provide details and
	an estimated valuation
	Interest after change
Part 3 - +Closed period
	Were the interests in the securities or contracts	No
	detailed above traded during a +closed period where
	prior written clearance was required?
	If so, was prior written clearance provided to allow	N/a
	the trade to proceed during this period?
	If prior written clearance was provided, on what	N/a
	date was this provided?

• See chapter 19 for defined terms. Appendix 3Y Page 2